Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNK001
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RNK001 is an allogeneic natural killer (NK) cell therapy generated ex vivo from umbilical cord blood-derived CD34+ hematopoietic stem and progenitor cells (HSPC). Developed by Radboud University Medical Center, the manufacturing process utilizes a combination of interleukin-15 (IL-15), interleukin-12 (IL-12), and the aryl hydrocarbon receptor (AhR) antagonist StemRegenin-1 (SR1) to produce a highly pure and functional NK cell product. RNK001 is primarily investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), where it aims to provide an anti-tumor response through the infusion of mature, activated NK cells expressing receptors such as NKG2D, DNAM-1, and natural cytotoxicity receptors (NCRs).
- Other names
- HSPC-NK cellsCD34+ progenitor-derived NK cells
02
Targets
CD226 (DNAX accessory molecule 1)NKG2D (Natural killer group 2 member D receptor)NCR1 (Natural cytotoxicity triggering receptor 1)NCR2 (Natural cytotoxicity triggering receptor 2)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))
Beyond the preview
Go deeper on RNK001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNK001.